Postmarketing Reports of Incomplete Dosing-Related Complications with Self-Injected PCSK9 Inhibitors: A Descriptive Study and Disproportionality Analysis

Overview

Journal BioDrugs

Specialties Allergy & Immunology
Genetics
Pharmacology

Date 2024 Jun 14

PMID 38874875

Authors

Richard H Woods

Affiliations

Soon will be listed here.

Abstract

Background: Evolocumab and alirocumab are self-injected proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors indicated for low-density lipoprotein cholesterol reduction. Complications in the use or functionality of self-injection devices may precipitate incomplete dosing.

Objective: This study sought to characterize postmarketing dosing failure reports involving self-injected PCSK9 inhibitors.

Methods: US Food and Drug Administration Adverse Event Reporting System (FAERS) [2016-second quarter of 2023] data were utilized for a disproportionality analysis. Eight self-injected comparator medications served as referents. Medical Dictionary for Regulatory Activities preferred terms indicating explicit or probable failure to administer a complete dose classified cases. Proportional reporting ratios (PRRs) > 2.0 and lower 95% confidence intervals (CIs) > 1.0 indicated disproportionality signals. US FDA Manufacturer and User Facility Device Experience (MAUDE) [2013-2023] data underwent a narrative review.

Results: During the study period, 194,781 (evolocumab, n = 152,831; alirocumab, n = 41,950) drug-event pairs and 43,725 (evolocumab, n = 38,489; alirocumab, n = 5236) cases reported to FAERS identified PCSK9 inhibitors. MAUDE contained six evolocumab reports, half describing dose omission, and no alirocumab reports. A potential dosing failure signal was detected for evolocumab (PRR 2.01; 95% CI 1.98-2.03), but not alirocumab (PRR 0.99; 95% CI 0.97-1.02), relative to pooled comparator reports. Across three case term subcategories, incomplete dosing disproportionality signals were further identified for evolocumab patient usage complication terms (PRR 3.44; 95% CI 3.38-3.50) and alirocumab device malfunction terms (PRR 2.09; 95% CI 1.98-2.22).

Conclusions: Proprotein convertase subtilisin kexin type 9 inhibitor incomplete dosing-related complications are frequently reported in the postmarketing setting. Systematic efforts to understand the incidence and mechanisms of dosing failure and associated patient burdens are needed.

References

Tsao C, Aday A, Almarzooq Z, Anderson C, Arora P, Avery C . Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. Circulation. 2023; 147(8):e93-e621. DOI: 10.1161/CIR.0000000000001123. View

Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes E . The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012; 380(9841):581-90. PMC: 3437972. DOI: 10.1016/S0140-6736(12)60367-5. View

Ray K, Ginsberg H, Davidson M, Pordy R, Bessac L, Minini P . Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control. Circulation. 2016; 134(24):1931-1943. PMC: 5147039. DOI: 10.1161/CIRCULATIONAHA.116.024604. View

Michos E, McEvoy J, Blumenthal R . Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease. N Engl J Med. 2019; 381(16):1557-1567. DOI: 10.1056/NEJMra1806939. View

Bucholz E, Rodday A, Kolor K, Khoury M, de Ferranti S . Prevalence and Predictors of Cholesterol Screening, Awareness, and Statin Treatment Among US Adults With Familial Hypercholesterolemia or Other Forms of Severe Dyslipidemia (1999-2014). Circulation. 2018; 137(21):2218-2230. PMC: 6381601. DOI: 10.1161/CIRCULATIONAHA.117.032321. View

Wall H, Ritchey M, Gillespie C, Omura J, Jamal A, George M . Vital Signs: Prevalence of Key Cardiovascular Disease Risk Factors for Million Hearts 2022 - United States, 2011-2016. MMWR Morb Mortal Wkly Rep. 2018; 67(35):983-991. PMC: 6132182. DOI: 10.15585/mmwr.mm6735a4. View

Gu J, Sanchez R, Chauhan A, Fazio S, Wong N . Lipid treatment status and goal attainment among patients with atherosclerotic cardiovascular disease in the United States: A 2019 update. Am J Prev Cardiol. 2022; 10:100336. PMC: 8968014. DOI: 10.1016/j.ajpc.2022.100336. View

Kim C, Sussman J, Mukamal K, Eades M, Anderson T . Trends in Primary Prevention Statin Use by Cardiovascular Risk Score From 1999 to 2018: A Repeated Cross-Sectional Study. Ann Intern Med. 2023; 176(12):1684-1688. PMC: 10910331. DOI: 10.7326/M23-1915. View

Arnold N, Koenig W . PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection. Curr Cardiol Rep. 2022; 24(11):1657-1667. PMC: 9729136. DOI: 10.1007/s11886-022-01782-6. View

10.

Roth E, Bujas-Bobanovic M, Louie M, Cariou B . Patient and Physician Perspectives on Mode of Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels. Clin Ther. 2015; 37(9):1945-1954.e6. DOI: 10.1016/j.clinthera.2015.07.008. View

11.

van den Bemt B, Gettings L, Domanska B, Bruggraber R, Mountian I, Kristensen L . A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience. Drug Deliv. 2019; 26(1):384-392. PMC: 6442222. DOI: 10.1080/10717544.2019.1587043. View

12.

Antalfy A, Berman K, Everitt C, Alten R, Latymer M, Godfrey C . The Adherence and Outcomes Benefits of Using a Connected, Reusable Auto-Injector for Self-Injecting Biologics: A Narrative Review. Adv Ther. 2023; 40(11):4758-4776. PMC: 10567963. DOI: 10.1007/s12325-023-02671-2. View

13.

Evans S, Waller P, Davis S . Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2002; 10(6):483-6. DOI: 10.1002/pds.677. View

14.

Lee S, Kwon H, Park Y, Ko S, Choi Y, Yoon K . Statin Discontinuation after Achieving a Target Low Density Lipoprotein Cholesterol Level in Type 2 Diabetic Patients without Cardiovascular Disease: A Randomized Controlled Study. Diabetes Metab J. 2014; 38(1):64-73. PMC: 3950197. DOI: 10.4093/dmj.2014.38.1.64. View

15.

Stroes E, Guyton J, Lepor N, Civeira F, Gaudet D, Watts G . Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. J Am Heart Assoc. 2016; 5(9). PMC: 5079013. DOI: 10.1161/JAHA.116.003421. View

16.

Dent R, Joshi R, Djedjos C, Legg J, Elliott M, Geller M . Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting. Springerplus. 2016; 5:300. PMC: 4783317. DOI: 10.1186/s40064-016-1892-3. View

17.

Farnier M, Colhoun H, Sasiela W, Edelberg J, Asset G, Robinson J . Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years. J Clin Lipidol. 2017; 11(4):986-997. DOI: 10.1016/j.jacl.2017.05.016. View

18.

Tatlock S, Arbuckle R, Sanchez R, Grant L, Khan I, Manvelian G . Psychometric Evaluation of a Treatment Acceptance Measure for Use in Patients Receiving Treatment via Subcutaneous Injection. Value Health. 2017; 20(3):430-440. DOI: 10.1016/j.jval.2016.09.2410. View

19.

Li Z, Easton R . Practical considerations in clinical strategy to support the development of injectable drug-device combination products for biologics. MAbs. 2017; 10(1):18-33. PMC: 5800388. DOI: 10.1080/19420862.2017.1392424. View

20.

Machal M . Framework for creating a qualified medical device development tool of autoinjectors. Front Med Technol. 2023; 5:1281403. PMC: 10733859. DOI: 10.3389/fmedt.2023.1281403. View